3Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice:A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American HeartAssociatio. Circulation ,2003,107 ( 3 ) :499-511.
4Zhang H, Cook D. Cerebral smooth muscle potassium channel and their possible role in the management of vasospasm. Pharmacol Toxicol,2004,75 ( 6 ) : 327-336.
5Spencer CG, Martin SC, Felmmlen DC, et al. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglog Scandinavian Cardiae Outeomes Trail.Int J Cardiol,2007,94(223) :293-300.
6Vyzantiadis T.Karagiannis A.Douma S.et al Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension Clin Exp Hypertens.2006.28(7):603-609.
7Navarro S, Ricart M, Medina P, et al. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br J Hecmatol, 2004,126(4) :550-556.
